drugset
drugset / Trial / NCT00499629

Study Evaluating the Safety of FXR-450 in Healthy Subjects

NCT00499629 ↗

Phase 1 Completed 64 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupQuadruple-blind

Summary

The primary purpose of the study is to evaluate the safety of FXR-450 in healthy subjects. This study will also evaluate pharmacokinetics (PK) of FXR-450 in healthy subjects.

Timeline

Start
2007-10
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator TUROFEXORATE ISOPROPYL Small molecule — Oral

Indications

No indication recorded.